Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject was previously diagnosed with multiple myeloma based on standard diagnostic criteria, as follows.~* Major criteria:~  1. Plasmacytomas on tissue biopsy.~ 2. Bone marrow plasmacytosis (\> 30% plasma cells).~ 3. Monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin G (IgG) \>3.5 g/dL or immunoglobulin A (IgA) \> 2.0 g/dL; kappa or lambda light chain excretion \> 1 g/day on 24 hour urine protein electrophoresis.~* Patients must have relapsed or refractory disease (refractory is defined as progression during treatment or within 60 days after the completion of treatment) requiring 2nd or 3rd line therapy~* Patients refractory to a combination of lenalidomide and dexamethasone will not be eligible. Patients may have received lenalidomide and/or dexamethasone~Exclusion Criteria:~* Renal insufficiency (serum creatinine levels \> 3 mg/dL)..~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).~* Known hypersensitivity to thalidomide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).